NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer - NICE TAG TA424

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer - NICE TAG TA424

1.1 Pertuzumab, in combination with trastuzumab and chemotherapy, is recommended, within its marketing authorisation, as an option for the neoadjuvant treatment of adults with human epidermal growth factor receptor 2 (HER2)‑positive breast cancer; that is, in patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence. It is recommended only if the company provides pertuzumab with the discount agreed in the patient access scheme.

https://www.nice.org.uk/guidance/ta424

Site by Devopa
© Copyright 2019 NHS. All rights reserved.